Cambridge Cognition

Cambridge Cognition is a UK-based neurotechnology company specializing in digital cognitive assessment tools used to measure brain health and cognitive function. Their flagship product, CANTAB (Cambridge Neuropsychological Test Automated Battery), is a validated suite of computerized neuropsychological tests that objectively measure attention, memory, executive function, and other key cognitive domains. These digital tools have been designed and refined over decades to provide precise, reliable measurements of cognitive performance across diverse populations. CANTAB is deployed globally in clinical trials, academic research institutions, and brain health studies, making it a cornerstone technology for understanding cognitive changes and neurodegenerative conditions.

The company has established itself as a trusted partner for pharmaceutical companies, academic institutions, and clinical research organizations worldwide. Their validated assessments are widely used in drug development programs, particularly for conditions like Alzheimer's disease, Parkinson's disease, depression, and other neurological and psychiatric disorders. As a publicly listed company on AIM under the ticker COG, Cambridge Cognition has built a substantial market presence in the cognitive health space, with their tools integrated into hundreds of major clinical trials and longitudinal studies. This established track record and regulatory acceptance have made CANTAB the gold standard for objective cognitive measurement in research and clinical settings.

Cambridge Cognition is critical to the neurotech industry because they have solved the longstanding problem of how to objectively and consistently measure cognitive function at scale. While cognitive assessment has traditionally relied on subjective clinical observation or paper-based tests, CANTAB provides standardized, quantifiable data that is essential for developing and validating new treatments for brain disorders. As the prevalence of cognitive decline and neurodegenerative diseases rises globally, the need for reliable, digital cognitive assessment tools becomes increasingly important for early detection, treatment monitoring, and drug development. Their work enables faster innovation in cognitive health while providing the rigorous measurement standards required by regulators and the scientific community.